Johnson & Johnson Family of Companies
NEWS
Janssen Pharmaceutical of Johnson & Johnson released new long-term data from the open-label period of its Phase III VOYAGE 1 clinical trial.
Citing “sources familiar with the matter,” The Wall Street Journal reported that the agreement, should it be reached, would ultimately settle the matter for the company related to sales of Duragesic and Nucynta.
What makes an organization a desirable employer? Do they need to be a large company with a recognizable name? Should the organization pay their employees more than others?
GlobalData recently published their top 20 global pharma companies categorized by market capitalization in the first quarter of 2019.
The jury found the company failed to warn patients of a side effect causing young men who used the drug to grow breasts (gynecomastia).
Johnson & Johnson reached a $20 million settlement agreement with two Ohio counties for its role in the opioid crisis ahead of a watershed trial set to take place later this month involving multiple companies and lawsuits.
According to the second biennial 2019 Life Sciences Ideal Employer Report by BioSpace, the top three most important attributes cited by life sciences professionals around the world are the opportunity to do interesting and meaningful work, a competitive salary and health benefits.
Erleada is an androgen receptor inhibitor approved for non-metastatic castration-resistant prostate cancer.
The Janssen Pharmaceutical Companies of Johnson & Johnson announced that the European Commission has approved the expanded use of ustekinumab for the treatment of adults with moderately to severely active ulcerative colitis, who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic or have medical contraindications to such therapies.
JOBS
IN THE PRESS